BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17388218)

  • 21. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
    Powell AM; Robson AM; Russell-Jones R; Barlow RJ
    Br J Dermatol; 2009 May; 160(5):994-8. PubMed ID: 19222462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical imiquimod for periocular lentigo maligna.
    Demirci H; Shields CL; Bianciotto CG; Shields JA
    Ophthalmology; 2010 Dec; 117(12):2424-9. PubMed ID: 20591492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imiquimod as an antiaging agent.
    Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R
    J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imiquimod in the treatment of extensive recurrent lentigo maligna.
    Kamin A; Eigentler TK; Radny P; Bauer J; Weide B; Garbe C
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):51-2. PubMed ID: 15692515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod.
    Ramsdell AM; Zeitouni N
    Dermatol Surg; 2009 Feb; 35(2):287-90. PubMed ID: 19215272
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
    Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
    J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures.
    Tio D; van der Woude J; Prinsen CAC; Jansma EP; Hoekzema R; van Montfrans C
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):616-624. PubMed ID: 27987308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.
    Kirtschig G; van Meurs T; van Doorn R
    Acta Derm Venereol; 2015 Jan; 95(1):83-5. PubMed ID: 24696093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients.
    Ly L; Kelly JW; O'Keefe R; Sutton T; Dowling JP; Swain S; Byrne M; Curr N; Wolfe R; Chamberlain A; Haskett M
    Arch Dermatol; 2011 Oct; 147(10):1191-5. PubMed ID: 22006136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remission of extensive lentigo maligna after treatment with imiquimod.
    Piazza CD; Sampaio SA
    An Bras Dermatol; 2009; 84(1):82-4. PubMed ID: 19377765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of imiquimod-treated lentigo maligna.
    Papanikolaou M; Lawrence CM
    Clin Exp Dermatol; 2019 Aug; 44(6):631-636. PubMed ID: 30663131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
    Woodmansee CS; McCall MW
    Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
    [No Abstract]   [Full Text] [Related]  

  • 35. Videodermatoscopy of lentigo maligna treated with imiquimod.
    Micali G; Lacarrubba F; Nardone B; Nasca MR
    J Drugs Dermatol; 2008 Nov; 7(11):1077-80. PubMed ID: 19110742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients.
    Buettiker UV; Yawalkar NY; Braathen LR; Hunger RE
    Arch Dermatol; 2008 Jul; 144(7):943-5. PubMed ID: 18645150
    [No Abstract]   [Full Text] [Related]  

  • 37. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
    Mora AN; Karia PS; Nguyen BM
    J Am Acad Dermatol; 2015 Aug; 73(2):205-12. PubMed ID: 26088690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conservative treatment of lentigo maligna with topical imiquimod 5% cream: a case report.
    Lobo Y; Templeman R
    Dermatol Online J; 2020 Jul; 26(7):. PubMed ID: 32898412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amelanotic lentigo maligna managed with topical imiquimod.
    Lapresta A; GarcĂ­a-Almagro D; Sejas AG
    J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
    [No Abstract]   [Full Text] [Related]  

  • 40. Interventions for melanoma in situ, including lentigo maligna.
    Tzellos T; Kyrgidis A; Mocellin S; Chan AW; Pilati P; Apalla Z
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010308. PubMed ID: 25526608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.